Vaxart 提供代理投票的最新更新，並敦促截至 2022 年 4 月 11 日記錄的所有股東在 2022 年 8 月 3 日下午 11:59 （美國東部時間）前投票。
July 27, 2022 15:28 ET
|
Vaxart, Inc.
關鍵提案 #2 需要額外 0.9% 的流通股投票才能通過 領先的獨立代理諮詢公司 ISS 和 Glass Lewis 支持提案 #2 加利福尼亞州南舊金山, July 28, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) 今天敦促其截至 2022 年 4 月 11...
Vaxart biedt nieuwe update over stemmen bij volmacht en dringt er bij alle op 11 april 2022 geregistreerde aandeelhouders op aan om vóór 3 augustus 2022 om 23:59 uur ET te stemmen
July 27, 2022 15:28 ET
|
Vaxart, Inc.
Het hoofdvoorstel #2 heeft nog 0,9% van de uitstaande aandelenstemmen nodig om aangenomen te worden Toonaangevende onafhankelijke stemadviesbureaus, ISS en Glass Lewis, ondersteunen het voorstel #2 ...
Vaxart ofrece una nueva actualización sobre el voto por delegación e insta a todos los accionistas registrados a fecha del 11 de abril de 2022 a votar antes del 3 de agosto de 2022, a las 11:59 p. m. ET.
July 27, 2022 15:28 ET
|
Vaxart, Inc.
La Propuesta Clave n.º 2 necesita un 0,9 % adicional de votos de las acciones en circulación para su aprobación Las Firmas Asesoras Independientes destacadas, ISS y Glass Lewis, apoyan la Propuesta...
Vaxart fornisce un nuovo aggiornamento sul voto per delega e invita tutti gli azionisti registrati all’11 aprile 2022 a votare entro il 3 agosto 2022, alle 23:59 ET
July 27, 2022 15:28 ET
|
Vaxart, Inc.
La proposta chiave n. 2 necessita di un ulteriore 0,9% di voti delle azioni in circolazione per essere approvata Le principali società di consulenza indipendente, ISS e Glass Lewis, sostengono la...
Vaxart fournit une nouvelle mise à jour sur les votes par procuration et exhorte tous les actionnaires inscrits au 11 avril 2022 à voter avant le 3 août 2022 à 23h59 (heure de l'Est)
July 27, 2022 15:28 ET
|
Vaxart, Inc.
La proposition clé n° 2 a besoin de 0,9 % des voix conférées par des actions en circulation pour être approuvée Les cabinets indépendants de conseil en procuration de premier plan ISS et Glass Lewis...
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
July 27, 2022 08:00 ET
|
Vaxart, Inc.
Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., July 27,...
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
July 20, 2022 08:30 ET
|
Vaxart, Inc.
Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples Vaxart will leverage data gained from trial as it...
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
July 14, 2022 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior...
Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET
July 01, 2022 09:00 ET
|
Vaxart, Inc.
Key Proposal #2 has received significant support, but additional votes are needed for approval Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO,...
Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model
June 30, 2022 08:00 ET
|
Vaxart, Inc.
Model will be used in Vaxart’s Phase II Omicron Challenge Trial Open Orphan subsidiary hVIVO to manufacture challenge virus and conduct characterization study SOUTH SAN FRANCISCO, Calif.,...